Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Mitomycin.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Mitomycin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Mitomycin.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Mitomycin.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mitomycin.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mitomycin.
Advertisement
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mitomycin.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Mitomycin.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Mitomycin.
Advertisement
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Mitomycin.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Mitomycin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Mitomycin.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Mitomycin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitomycin.
Clozapine
The risk or severity of adverse effects can be increased when Mitomycin is combined with Clozapine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Mitomycin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Mitomycin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Mitomycin.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitomycin.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Mitomycin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Mitomycin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Mitomycin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Mitomycin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Mitomycin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Mitomycin.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Mitomycin.
Fingolimod
Mitomycin may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mitomycin.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Mitomycin.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Mitomycin.
Leflunomide
The risk or severity of adverse effects can be increased when Mitomycin is combined with Leflunomide.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Mitomycin.
Natalizumab
The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Mitomycin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Mitomycin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitomycin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Mitomycin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Mitomycin.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Mitomycin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mitomycin.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Mitomycin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Mitomycin.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Mitomycin.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Mitomycin.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Mitomycin.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Mitomycin.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Mitomycin.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitomycin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Mitomycin.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mitomycin.
Tofacitinib
Mitomycin may increase the immunosuppressive activities of Tofacitinib.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Mitomycin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Mitomycin.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Mitomycin.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Mitomycin.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Mitomycin.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Mitomycin.
Vincamine
The risk or severity of adverse effects can be increased when Vincamine is combined with Mitomycin.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.
Vindesine
The risk or severity of adverse effects can be increased when Vindesine is combined with Mitomycin.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mitomycin.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Mitomycin.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Mitomycin.
